APA (7th ed.) Citation

Hadji, P., Marmé, F., & Schneeweiss, A. (2019). The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial. Journal of bone oncology, 14, . https://doi.org/10.1016/j.jbo.2018.09.010

Chicago Style (17th ed.) Citation

Hadji, Peyman, Frederik Marmé, and Andreas Schneeweiss. "The Impact of Mammalian Target of Rapamycin Inhibition on Bone Health in Postmenopausal Women with Hormone Receptor-positive Advanced Breast Cancer Receiving Everolimus Plus Exemestane in the Phase IIIb 4EVER Trial." Journal of Bone Oncology 14 (2019). https://doi.org/10.1016/j.jbo.2018.09.010.

MLA (9th ed.) Citation

Hadji, Peyman, et al. "The Impact of Mammalian Target of Rapamycin Inhibition on Bone Health in Postmenopausal Women with Hormone Receptor-positive Advanced Breast Cancer Receiving Everolimus Plus Exemestane in the Phase IIIb 4EVER Trial." Journal of Bone Oncology, vol. 14, 2019, https://doi.org/10.1016/j.jbo.2018.09.010.